Nonclassical congenital adrenal hyperplasia: targets of treatment and transition

Pediatr Endocrinol Rev. 2014 Dec;12(2):224-38.

Abstract

Nonclassical congenital adrenal hyperplasia (NCCAH) caused by 21-hydroxylase deficiency is a common autosomal recessive condition that can present with a wide range of hyperandrogenemic signs in childhood or adulthood. The management of children with NCCAH can be challenging, as no universally accepted guidelines have been established. Our goal was to evaluate the literature and develop an evidence-based guideline for the medical management of children and adolescents with NCCAH. We reviewed the published literature and used the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) system when appropriate to grade the evidence and provide recommendations for the medical management of children and adolescents with NCCAH, appropriate transition practices from pediatric to adult endocrine care, and psychological issues that should be addressed in parents and patients with NCCAH. We offer recommendations, based on the available evidence, for the management of NCCAH at the different developmental stages from diagnosis through transition to adulthood.

Publication types

  • Consensus Development Conference

MeSH terms

  • Adrenal Hyperplasia, Congenital / diagnosis*
  • Adrenal Hyperplasia, Congenital / therapy*
  • Child
  • Endocrinology / standards*
  • Evidence-Based Medicine / standards
  • Humans
  • Pediatrics / standards*
  • Practice Guidelines as Topic*

Supplementary concepts

  • Congenital adrenal hyperplasia due to 21 hydroxylase deficiency